Company Directory / research

PrivateFor profitresearchSödertälje, Sweden
Anocca is a drug and immunotherapy developer aiming to uncover the therapeutic potential of T-cell immunity.
Size
11-50 people: larger than 33% of companies with a size listed
Age
12 years old.
Reach
Website ranked #4,490,483 in the world for traffic, about 2k visits a month.
BiotechnologyHealth CareTherapeutics
Funding, as listed
$110M currency not stated
What the source datasets report. We have not watched these rounds ourselves.
Everything the source datasets list about Anocca, field by field. Contact details are held but never shown.
The company
Where
Size and reach
Funding, as listed
About this record
Growth, as the source summarises it
Anocca may be growing as it has entered into a licensing agreement with EmendoBio for gene editing technology, which suggests an expansion of its capabilities in the biotechnology and therapeutics industry. This strategic move indicates that Anocca is actively seeking to enhance its immunotherapy development portfolio, which could potentially lead to new product offerings and collaborations. The licensing agreement could also provide Anocca with access to new technologies and intellectual property, further supporting its growth trajectory in the health care sector.
Summaries written by the source dataset, not by us, and not checked.
research in Sweden.
From the company datasets we hold (Crunchbase, LinkedIn and Apollo listings), as listed there; 41,197 companies in Sweden and 5,926,251 in all. We hold no contact details for public display. Correct this, or ask for it to be removed.